Recent Updates
Recently added Catalysts

MK0906, finasteride/ Duration of Treatment: 48 Weeks

Phase 3

Androgenetic Alopecia | Small molecule | Dermatology |Organon & Co.|Trials Updated: Aug 15, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials2
Total Enrollment955

FDA Designations

No designations recorded

MK0906, finasteride/ Duration of Treatment: 48 Weeks clinical trials

MK0906, finasteride/ Duration of Treatment: 48 Weeks · 2 trials · 2 indications

Phase 3 2
NCT00127179A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)Benign Prostatic Hyperplasia
COMPLETED600 Analytics
NCT00396175Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)Androgenetic Alopecia
COMPLETED355 Analytics
PHASE3COMPLETED
A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)
Benign Prostatic Hyperplasia
NCT00127179600
Unlock trial analytics
PHASE3COMPLETED
Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)
Androgenetic Alopecia
NCT00396175355
Unlock trial analytics

Study Endpoints

Primary Endpoints

Change from baseline in the International Prostate Symptom Score
Serum Prostatic Specific Antigen (PSA) after 48 weeks of treatment

Secondary Endpoints

Change from baseline in QOL - index
Change from baseline in maximum urinary flow rate, %
Change from baseline in Prostate volume
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
MK0906, finasteride / Duration of Treatment: 48 weeksDRUG -
Comparator: placebo / Duration of Treatment: 48 weeksDRUG -
MK0906, finasteride / Duration of Treatment : 48 WeeksDRUG -
Comparator : placebo (unspecified) / Duration of Treatment : 48 WeeksDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range50 Years to 79 Years
SexMALE
Healthy VolunteersNo

Inclusion Criteria: * Patients with benign prostatic hyperplasia Exclusion Criteria: * Patients who are suspected to be suffering from prostatic cancer

Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Organon & Co. (OGN)Pipeline, catalysts, financials, insiders and newsAndrogenetic Alopecia disease mapEvery company developing for Androgenetic Alopecia, by stage and capitalFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with MCompanies A to ZEvery biotech and pharma company we track